secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2026-07-27T12:05:15+00:00
Accession:  0001193125-26-316928
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Biosciences appoints Adrian Quartel as Chief Medical Officer
-------------------------------------------------------------------

- Dr. Quartel replaces Dr. Kirk Ways, who had been serving as Interim CMO; Dr. Ways remains on the Board.
- Quartel brings 25+ years pharma experience, most recently CMO of Zevra Therapeutics.
- He previously led global medical affairs at BioMarin, launching six rare-disease treatments.
- Quartel holds an M.D. from Erasmus University and is board certified in pharmaceutical medicine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000119312526316928/0001193125-26-316928-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000119312526316928/sprb-20260727.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-316928

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer